



Colombian Journal of Anesthesiology

Revista Colombiana de Anestesiología

www.revcolanest.com.co

OPEN

Wolters Kluwer

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: main concepts for anesthesiologists

Cirugía citorrreductiva y quimioterapia intraperitoneal hipertérmica: Conceptos importantes para el anesestesiólogo

Bibiana Escobar^{a,b}, Paula Medina-Piedrahita^a, Paula Gómez-Henao^b, Andrés Higuera-Palacio^b, Mauricio García-Mora^c, Joaquín Octavio Ruiz-Villa^a, Crystian Borrero-Cortés^a

^a Anaesthesia Department, Medical School, Universidad Nacional de Colombia. Bogotá, Colombia

^b Anaesthesia and Perioperative Medicine Service. Instituto Nacional de Cancerología. Bogotá, Colombia

^c Breast and Soft Tissue Surgery Service, Instituto Nacional de Cancerología. Bogotá, Colombia.

Keywords: Hyperthermia, Induced, Drug Therapy, Combination, Anesthesiology, Intestinal Neoplasms, Peritoneal Neoplasms

Palabras clave: Hipertermia inducida, Quimioterapia Combinada, Anestesiología, Neoplasias intestinales, Neoplasias Peritoneales

Abstract

Introduction: Hyperthermic intraperitoneal chemotherapy (HIPEC) is a complex therapeutic procedure used to complement cytoreductive surgery and intravenous chemotherapy for the management of primary peritoneal neoplasms and peritoneal carcinomatosis.

Objectives: To review considerations regarding the surgical procedure, physiological changes associated with fluid, blood and protein loss, increase in intra-abdominal pressure, metabolic rate, and systemic hyperthermia, from the perspective of the anesthesiologist.

Methods: A nonsystematic search was conducted in the Medline/PUBMED and Google Academics databases using the terms cytoreductive surgery, hyperthermia, HIPEC, peritoneal carcinomatosis, and Sugarbaker. No limits for publication dates

were used. The articles were reviewed independently by each of the authors, and the final text was edited and approved by the main author.

Results: Overall, 151 articles were identified, and, of these, 64 were included in the review. The aspects studied included the surgical technique, physiological changes during the procedure, and anesthetic management.

Conclusion: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is a therapeutic option for patients with peritoneal carcinomatosis. This procedure involves risks for the patient, first because of an initial phase which involves fluid and blood loss, and, second, because the hyperthermic phase gives rise to a hyperdynamic state with hemodynamic instability. Anesthesiologists must be familiar with the basic aspects of management to reduce complications and improve patient outcomes.

How to cite this article: Escobar B, Medina-Piedrahita P, Gómez-Henao P, Higuera-Palacio A, García-Mora M, Ruiz-Villa JO, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: main concepts for anaesthetists. Rev Colomb Anestesiología. 2018;46:134-142.

Read the Spanish version of this article: <http://links.lww.com/RCA/A35>.

Copyright © 2018 Sociedad Colombiana de Anestesiología y Reanimación (S.C.A.R.E.). Published by Wolters Kluwer. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Correspondence: Carrera 51 No. 103 B – 60. Bogotá, Colombia. E-mail: bjescobars@unal.edu.co

Rev Colomb Anestesiología (2018) 46:2

<http://dx.doi.org/10.1097/CJ9.0000000000000025>

Resumen

Introducción: La quimioterapia intraperitoneal hipertérmica (*Hyperthermic Peritoneal Chemotherapy - HIPEC*) es un procedimiento terapéutico complejo, utilizado como complemento de la cirugía citorréductiva (CCR) y de la quimioterapia endovenosa, para el manejo de las neoplasias peritoneales primarias y la carcinomatosis peritoneal.

Objetivos: Revisar desde la perspectiva del anestesiólogo, conceptos generales sobre el procedimiento quirúrgico, los cambios fisiológicos asociados a la pérdida de fluidos, sangre y proteínas, al aumento de la presión intra-abdominal, la tasa metabólica y la hipertermia sistémica.

Métodos: Se realizó una búsqueda no sistemática en las bases de datos Medline/PUBMED y Google Academics utilizando los términos cytoreductive surgery, hyperthermia, HIPEC, peritoneal carcinomatosis y Sugarbaker. No se establecieron límites para fecha de publicación. Los artículos fueron revisados de manera independiente por cada uno de los autores y el texto final fue editado y aprobado por el autor principal.

Resultados: Fueron identificados 151 artículos, de los cuales se incluyeron 64 para la revisión. Los aspectos estudiados incluyeron la técnica quirúrgica, los cambios fisiológicos durante el procedimiento y el manejo anestésico.

Conclusión: La cirugía citorréductiva más quimioterapia intraperitoneal hipertérmica es una alternativa terapéutica para los pacientes con carcinomatosis peritoneal. Este procedimiento supone riesgos para el paciente, tanto por una primera fase que implica pérdidas de fluidos y sangre, como por la fase de hipertermia que genera un estado hiperdinámico con inestabilidad hemodinámica. El anestesiólogo debe conocer los aspectos fundamentales del manejo para disminuir las complicaciones y mejorar los desenlaces de los pacientes.

Introduction

In 1980, Dr John S. Spratt submitted a report on abdominal cytoreductive surgery involving peritonectomy and the infusion of hyperthermic intraperitoneal chemotherapy (HIPEC) in the same surgical stage.¹ Later, Dr Paul H. Sugarbaker developed and disseminated this surgical technique as part of the management of cancer patients.^{2,3}

Cytoreductive surgery (CRS) consists of the resection of the tumor and the affected areas of the parietal and visceral peritoneum. This is followed by HIPEC, consisting of the perfusion of the peritoneal cavity with a solution heated to 42°C or 43°C, in which the chemotherapeutic agents are diluted.^{4,5}

Cytoreductive surgery with HIPEC is the treatment of choice for patients with pseudomixoma peritonei and peritoneal carcinomatosis due to primary rectal, ovarian, and colon tumors. One, 3, and 5-year survival ranges from 19 to 38 months.⁶⁻⁹ Perioperative mortality is close to 12%, the main causes being sepsis and multiple organ failure. Complications may occur in up to 33% of patients. The

causes of mortality are anastomotic leaks (0%–9%), fistulas (0%–23%), gut perforation (0%–10%), intraperitoneal sepsis (0%–14%), abscess (0%–37%), ileus (0%–86%), and deep vein thrombosis/pulmonary thromboembolism (0%–9%).¹⁰⁻¹³

The purpose of this review is to highlight aspects of the surgical intervention that are relevant for the anesthetist.

Methodology

Nonsystematic or narrative review of the literature was done (Fig. 1). A nonsystematic search with no date limits was conducted in Medline/PUBMED, ScienceDirect, and Google Academics. The terms used were “(“Hyperthermia, Induced”[Mesh] AND “Peritoneal Neoplasms”[Mesh]) AND “Surgical Procedures, Operative”[Mesh] AND “Chemotherapy, Cancer, Regional Perfusion”[Mesh] AND “Anaesthesia”[Mesh], “Cytoreductive surgery Peritoneal Neoplasms Chemotherapy Anaesthesia management Sugarbaker perioperative care”, “Cytoreductive surgery Induced Hyperthermic Peritoneal Neoplasms Chemotherapy Cancer Regional Perfusion Anaesthesia management Sugarbaker perioperative care Intraoperative management Guidelines”. Duplicate articles, and also articles on extra-abdominal carcinomatosis and those with only the abstract were removed. The search was expanded to articles referenced in the results section of previously selected papers. Finally, all the articles were reviewed independently by each of the authors, and the final text was edited by the main author. The aspects discussed in this review include surgical technique, physiological changes during the procedure, and anesthetic management.

Surgical procedure

Indications for CRS plus HIPEC include pseudomixoma peritonei, malignant peritoneal mesothelioma, peritoneal sarcomatosis, and peritoneal carcinomatosis due to colorectal, gastric, and tubal/ovarian cancer. HIPEC may also be used as an adjunct and palliative therapy for uncontrolled ascites.

The surgical procedure consists of 2 phases,¹²⁻¹⁶ described in the following subsections.

Cytoreductive surgery plus peritonectomy

Resection of the primary tumor and all grossly visible peritoneal metastases through peritonectomy, which includes^{2,17} removal of the greater omentum; the right upper quadrant; the lesser omentum, splenectomy, cholecystectomy, and retrocavity bursectomy; and peritonectomy of the left upper quadrant and pelvis with en bloc resection of the rectosigmoid junction and cul-de-sac.

HIPEC

Once cytoreductive surgery/peritonectomy is completed and depending on the peritoneal cancer index (Fig. 2), a decision is made of whether to initiate perfusion. For





Figure 1. Methodology for nonsystematic review of the literature (www.prisma-statement.org). Source: Authors.

HIPEC, the patient is placed in lithotomy position with the legs in 90° of abduction. Four to 5 cannulas are introduced into the peritoneal cavity: 2 are located in the right subdiaphragmatic and pelvic positions and are used for infusing the chemotherapy solution, whereas the other 2 or 3 cannulas, placed in the left diaphragmatic, subhepatic, and pelvic positions, are used for fluid drainage. The cannulas are connected to the bypass circulation system of the HIPEC machine. Two techniques may be used: open (Coliseum) or closed. In the closed technique, the edges of the incision are sutured temporarily as opposed to the open technique where the edges are covered with a plastic material or a steam evacuator is placed under the plastic sheet. Temperature is monitored continuously by means of 6 probes (superior and inferior abdominal, at entry and exit catheters, and at the level of the rectum and the esophagus).^{15,17} The perfusate volume (dialysis solution or normal saline solution) is 3 to 4L for the open technique and 6L for the closed technique, to ensure homogeneous

distribution in the peritoneal cavity without inducing excess abdominal distension. With the cannulas in place and after the circuit is purged, recirculation is initiated at a flow rate of 600 to 1000 mL/min (Fig. 3). During heating, the fluid is perfused at a temperature of 44°C to 46°C until intraperitoneal temperature is 41°C. At that point, chemotherapy is administered in the bypass circulation system at exact doses calculated on the basis of the weight in kilograms for each agent. For the 2 techniques, the operating table is tilted right and left, Trendelenburg and anti-Trendelenburg during the procedure to facilitate movement of the fluid inside the peritoneal cavity. After recirculation at the end of the perfusion, the fluid is drained rapidly making sure no suction injuries are created. The cavity is opened again, the secondary anastomosis to the intestinal resections performed for gut involvement are made, and the abdominal wall is closed. The operating table must have conduction warming/cooling blankets.¹⁵



Regions	Lesion Size	Lesion sizeScore (the largest implants scored in each regions)
0 Central	_____	LS 0 No tumor seen
1 Right upper	_____	LS 1 ≤ 0.5 cm
2 Epigastrium	_____	LS 2 > 0.5 cm to ≤ 5.0 cm
3 Left upper	_____	LS 3 > 5 cm or confluence
4 Left flank	_____	
5 Left lower	_____	
6 Pelvis	_____	
7 Right lower	_____	
8 Right flank	_____	
9 Upper jejunum	_____	
10 Lower jejunum	_____	
11 Upper ileum	_____	
12 Lower ileum	_____	
PCI	0-39	

Figure 2. Staging system using the peritoneal cancer index (PCI) for peritoneal carcinomatosis. The abdomen and pelvis are divided into 12 regions. The size of the lesions of the largest implants are scored (from 0 to 3) in each abdominopelvic region, and a numerical score ranging from 1 to 39 is obtained.

Source: Taken with permission from Roviello et al.¹¹

Depending on tumor origin, several protocols have been developed, including the use of oxaliplatin, cisplatin, doxorubicin, leucovorin, and so on.¹⁸ The heat from HIPEC increases chemotherapy penetration into the tissues and the toxicity of certain agents, and has an antitumor effect.¹⁸⁻²⁰

Physiological changes

Hyperthermia-induced changes

During HIPEC, core temperature rises to 40.5°C, producing peripheral vasodilation, increased oxygen uptake (VO₂) and metabolic rate, reduced systemic vascular resistance (SVR), drop in cardiac output (CO), and increase in heart rate (HR).^{21,22} These changes are consistent with the magnitude of the hyperthermia which usually reaches a maximum level 60 minutes after infusion initiation. This hyperdynamic circulatory state normalises slowly once temperature begins to

drop.²³⁻²⁵ A trial conducted to compare the physiological effects of HIPEC at different degrees of temperature found that perfusion at 42.5±0.5°C was safe, with minimal system alterations, whereas higher temperatures affected anastomosis healing.²⁶

Shime et al²⁴ presented 11 patients managed with pulmonary artery catheter and described significant changes between the time before hyperthermia and 30 minutes into the process, including increase in HR, a drop in mean arterial pressure (MAP), a reduction in SVR, and an increase in cardiac output. Using esophageal Doppler, Esquivel et al²⁷ assessed 15 patients taken to HIPEC (open technique) and found an increase in CO, a drop in SVR, increased HR, and increased end-tidal CO₂; pulmonary artery catheters were used in 2 of these patients, and adequate correlations were observed in terms of the determination of hemodynamic variables. Noninvasive monitoring with devices such as echo-Doppler helped guide intravenous fluid administration during the hyperthermic phase. Schmidt et al²² had similar findings and




Figure 3. Schematic representation of the HIPEC device.
Source: Taken with permission from Roviello et al.¹¹

also reported a drop in pH and excess base, associated with an increase in lactate which occurs as temperature rises. Shime et al²⁴ also reported an increase in VO_2 and a slight increase in extraction rate.

Other physiological alterations

Increase in airway pressure and right atrial pressure (RAP) due to elevated abdominal pressure after the initiation of chemotherapy perfusion.²² RAP variations are also due to tilt changes of the operating table during hyperthermia; consequently, other monitoring techniques must be used, such as pulmonary artery catheter and pulse wave analysis devices, or noninvasive measures using an esophageal Doppler probe.²¹

Perfusion inside the abdominal cavity leads to increased intra-abdominal pressure, affecting respiratory and hemodynamic function. Despite the impact of increased intra-abdominal pressure on renal function,²⁸⁻³⁰ Schmidt et al²² used creatinine values measured before and after the procedure as a marker of renal dysfunction, and found no alteration. Other changes include a drop in venous return, increase vascular resistance of the splanchnic bed, and reduction in residual functional capacity and lung compliance with secondary hypoxemia and hypercapnia.^{31,32} Depending on flow velocity of the perfusate, fluid volume and type, intra-abdominal pressure may vary between 12 and 26 mm Hg.²⁶

There is also a drop in platelet count and international normalize ratio (INR), and partial thromboplastin time (PTT) prolongation during HIPEC.²²

Adverse effects of chemotherapy

Table 1 describes the toxic effects associated with the chemotherapeutic agents used in HIPEC.^{21,33}

Anesthetic management

Preanesthetic assessment

This assessment must be focused on determining the risk inherent to the surgical technique, the risk of complications according to functional capacity and patient comorbidities, and the risk from anesthesia, including procedures such as approaching the airway, inserting catheters, or blood transfusions. The assessment must detect any conditions that require stabilization before the procedure.³⁴

Patients present abdominal distension, increased intra-abdominal pressure, and diminished functional residual capacity, predisposing to full stomach and aspiration.^{21,35} The patient must be prepared for prolonged major abdominal surgery (6-12 hours), with a high surgical risk due to bleeding from cytoreduction and peritonectomy, excess fluid exchange, protein loss, and risk of coagulopathy due to hypothermia and hemodilution during the first phase.³⁶ Tests must include complete blood count, renal function, blood sugar, albumin, and electrolytes.

Measuring prothrombin time (PT), PTT, INR, and fibrinogen³⁷ is recommended because hemodilution, protein loss, bleeding, and chemotherapy may induce coagulopathy.

Table 1. Chemotherapeutic agents and their effects

Class	Drug	Mechanism	Perioperative implications
Alkylating agents			
Platin	Cisplatin Oxaliplatin	DNA replication inhibition	Acute tubular necrosis Hypomagnesemia Peripheral sensory neuropathy
Nitrogen mustards	Melphalan	DNA chain reticulation	Pericarditis Pericardial effusion SSIHAD Seizures
Antimetabolites			
Anthracyclines	Doxorubicin	DNA synthesis interruption Type 2 topoisomerase inhibition	Cardiomyopathy EKG changes
Antitumor antibiotics	Mitomycin C	DNA and RNA synthesis interruption	Pulmonary hypertension Pneumonitis Pulmonary fibrosis
Pyrimidine analogs	Fluorouracil Gemcitabine	Pyrimidine antimetabolites that interfere with DNA synthesis	Ischemia/myocardial infarction Coronary vasospasm
Microtubule assembly inhibitors			
Taxanes	Paclitaxel Docetaxel	Inhibition of microtubule assembly	Bradycardia Dysautonomia Peripheral neuropathy
Others			
Topoisomerase 1 inhibitors	Irinotecan	DNA rupture	Cholinergic syndrome Neutropenia

Source: Copied and modified with permission from Sahai et al.³⁹

Given nutritional decline in carcinomatosis, and the association between hypoalbuminemia and a higher perioperative mortality risk, this parameter should be measured for intraoperative management.³⁵

Due to the deleterious effects of hyperthermia and increased intra-abdominal pressure on cardiac function and hemodynamic stability, CRS+HIPEC is considered a surgery associated with high cardiovascular (CV) risk. Diagnostic and CV risk stratification tests are applied in accordance with the American Heart Association/American College of Cardiology guidelines.^{36,38} It is useful to assess CV function in response to stress, and rule out heart failure and nonovert coronary heart disease, because all these conditions result in an ominous increase in intraoperative and postoperative complications. It is also

important to determine what chemotherapy has been administered to assess for cardiotoxicity in accordance with the institution's own protocols.³⁹

Considering that renal failure is a frequent postoperative complication due to chemotherapy toxicity,⁴⁰ risk factors need to be identified, including chronic obstructive pulmonary disease, liver disease, heart failure, and older age.⁴¹ Blood products must be in reserve, and availability of the intensive care unit (ICU) must be ensured for postoperative care.

Intraoperative management

Monitoring. Basic monitoring standards established both by the American Society of Anesthesiology (ASA)⁴² as by

the Colombian Society of Anaesthesiology and Resuscitation (SCARE) must be followed. Temperature and hemodynamic control is mandatory. Temperature in the perfusion cannulas and the peritoneal cavity needs to be checked constantly to ensure that the latter remains at 40 to 42°C. Patient core temperature must be monitored using electronic thermometers, usually in the esophageal location.²² Hemodynamic monitoring includes continuous invasive arterial pressure, cardiac output (invasive/noninvasive/minimally invasive),³⁵ and central venous catheter for venous gases and continuous venous saturation. Early case series described hemodynamic changes using pulmonary artery catheter; more recently, minimally invasive monitoring of cardiac output has been proposed using arterial pulse wave analysis devices and esophageal echocardiography Doppler.³⁵ The successful use of esophageal echo-Doppler has been described, providing continuous assessment of preload-associated variables (aortic blood flow, aortic ejection volume) and contractility-associated variables (left ventricular ejection time, diameter, peak velocity, and aortic acceleration) and allowing a more accurate management of fluid therapy and hemodynamic support.^{27,43} One of the largest case series reported good results using systolic volume variation as a guideline for fluid management, with the aim of maintaining that variation under 10% and mean arterial pressure within a 20% variation range in relation to initial preoperative parameters.⁴⁴

Temperature control measure. Temperature management requires awareness of the different phases of the procedure. During the first phase, because of bleeding, evaporation, and ascites drainage, hypothermia due to coagulation, metabolic homeostasis, and inflammatory response depend on temperature. Moreover, hypothermia creates a high risk of CV events.⁴⁵ Forced air heaters and fluid warming systems must be used.^{21,46} During the second phase, when hyperthermic chemotherapy infusion begins, body temperature rises progressively, even up to 40.5°C.^{22,27} This, in turn, increases metabolic rate, oxygen consumption, expired CO₂, and gives rise to metabolic acidosis. Normothermia must be restored using cold intravenous fluids, and active cooling by conduction and convection; additionally, ventilator settings must be adjusted for these new hypermetabolic conditions.²¹

Fluid management. High losses due to the drop in venous return require more careful replacement with volumes as high as 12 ml/k/h, to maintain intravascular volume and prevent renal dysfunction.³⁵ It is advisable to administer fluids based on beat-to-beat hemodynamic changes, because liberal fluid therapies result in worse outcomes.⁴⁷ Due to nephrotoxicity induced by agents such as mitomycin C and cisplatin, the recommendation is to maintain high urinary volumes with output between 50 and 150 mL

every 15 minutes.³⁵ In the literature, several case reports and descriptive studies^{35,48} mention the use of dopamine and furosemide for renal protection; however, furosemide in itself is a risk factor for postoperative renal dysfunction,⁴¹ has no evidence of conferring renal protection,⁴⁸ and its use is not recommended. As far as dopamine is concerned, it has not been shown to reduce the risk of renal injury and its use will depend on the patient's hemodynamic condition, and routine use is not recommended.⁴⁹ Multiple studies in animal models have shown the effectiveness of using n-acetylcysteine in the context of nephrotoxicity induced by chemotherapeutic agents such as cisplatin.⁵⁰⁻⁵³

There are no randomized controlled trials comparing crystalloids and synthetic colloids (gelatines and starches) in this procedure, but given the association of colloids with nephrotoxicity and coagulopathy in the setting of critically ill patients, it is suggested to avoid their use due to the impact of the surgery and the chemotherapeutic agents on these 2 systems.⁵⁴ The use of albumin (1.5 g/k/d) is indicated in the management of these patients, considering high volume and protein losses, and the subsequent drop in oncotic pressure.^{35,37,55}

Electrolyte, glycemia, and lactate management. Blood gases, electrolytes, lactate, blood sugar, hematocrit, fibrinogen, and serum proteins must be measured throughout the procedure. Under our protocol, an initial sample is taken at the time of central venous access, followed by samples every 2 hours during CRS, at the start of chemotherapy perfusion, and at the start of cavity closure. The most frequent electrolyte alteration is hypokalemia associated with the use of dialysis solution and forced diuresis, and there may be severe secondary alterations in response to the solution and also to the chemotherapeutic agent. If dextrose solutions are used, sodium status must be checked; cases have been reported of hyponatremia and hyperglycemia.⁵⁶⁻⁵⁸ The use of oxaliplatin, which must be administered in a dextrose solution, may predispose the patient to lactic acidosis, hyperglycemia, and hyponatremia.⁵⁷ Cisplatin may cause hypomagnesemia and be associated with cardiac arrhythmias.⁵⁸

Lactate must be interpreted carefully because it might not be associated with tissue hypoperfusion and other causes of hypernatremia need to be ruled out.⁵⁷ According to the protocol in our institution, blood sugar monitoring is done every 60 minutes.

Coagulation control. There is a risk of coagulopathy due to high fluid supply, protein loss, hyponatremia, bleeding, and the chemotherapeutic agent. The use of thromboelastography is advisable.^{21,22,35} Platelets, PT, PTT, INR, fibrinogen, and antithrombin III must be measured intraoperatively. There are reports in the literature of packed red blood cell and fresh frozen plasma transfusions in 50% of the patients intraoperatively, and in 28% of the patients postoperatively.²⁴

Postoperative management

Patients must be taken to the ICU. Total fluid loss will amount to 4 to 5L/d during the first postoperative days, with the consequent risk of hypovolemia and hypotension.

Thoracic epidural analgesia is recommended for pain management.⁵⁹⁻⁶² In a report describing pain management explicitly, a thoracic peridural catheter was used. In patients with no peridural catheter, mechanical ventilation lasted 10.3 hours (2.9–62.2 hours), whereas in patients with epidural analgesia, mechanical ventilation was used during 3.1 hours (0.5–24.8). Length of stay in the ICU was similar for the 2 groups. Epidural analgesia was associated with a lower requirement of intravenous opioids. Of the patients with epidural analgesia, 41% were extubated in the operating room.²² However, sympathetic block from the thoracic level may contribute to hypotension and hemodynamic instability in the setting of a hyperdynamic state caused by hyperthermia; additionally, there is a higher theoretical risk of epidural hematoma.^{63,64} Patient-controlled analgesia, either intravenous or epidural, may also be used up to 1 week postoperatively.²²

Conclusions

Cytoreductive surgery with peritonectomy entails risks for the patient, both during the first phase because of considerable fluid and blood loss, and also during the second phase where hyperthermia gives rise to a hyperdynamic state with a high risk of hemodynamic instability. The job of the anesthetist is aimed at reducing postoperative cardiac, pulmonary, and renal complications, and improving survival. This requires knowledge of all the aspects of this complex surgery, and continuing to build the evidence regarding the most recommended hemodynamic surveillance method, preoperative tests for assessing cardiac performance, the usefulness of intraoperative thromboelastography, nephroprotection efficacy, and the impact of regional analgesia techniques on tumor behavior, among other things.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Funding

The authors declare not having received funding for the preparation of this article.

Conflicts of interest

The authors declare having no conflict of interest.

References

1. Spratt JS, Adcock RA, Sherrill W, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. *Cancer Res* 1980;40:256–260.
2. Sugarbaker PH. Peritonectomy procedures. *Ann Surg* 1995;221:29–42.
3. Sugarbaker PH, Landy D, Pascal R. Intraperitoneal chemotherapy for peritoneal carcinomatosis from colonic or appendiceal cystadenocarcinoma: rationale and results of treatment. *Prog Clin Biol Res* 1990;354B:141–170.
4. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon's role. *Langenbecks Arch Surg* 1999;384:576–587.
5. González-Moreno S. Hyperthermic intraperitoneal chemotherapy: rationale and technique. *World J Gastrointest Oncol* 2010;2:68.
6. Chu D, Lang N, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. *Cancer* 1989;63:364–367.
7. Verwaal VJ, Bruin S, Boot H, et al. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. *Ann Surg Oncol* 2008;15:2426–2432.
8. Weber T, Roitman M, Link KH. Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. *Clin Colorectal Cancer* 2012;11:167–176.
9. Reuter NP, MacGregor JM, Woodall CE, et al. Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy. *Am J Surg* 2008;196:909–914.
10. Chua TC, Yan TD, Saxena A, et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. *Ann Surg* 2009;249:900–907.
11. Roviello F, Caruso S, Marrelli D, et al. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments. *Surg Oncol* 2011;20:e38–e54.
12. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. *Ann Surg Oncol* 2007;14:128–133.
13. Seretis C, Youssef H. Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a systematic review. *Eur J Surg Oncol* 2014;40:1605–1613.
14. Esquivel J, Farinetti A, Sugarbaker PH. [Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to proceed]. *G Chir* 1999;20:81–86.
15. Macrì A. Rationale and techniques of cytoreductive surgery and peritoneal chemohyperthermia. *World J Gastrointest Oncol* 2011;3:169.
16. Huang C-Q, Min Y, Wang S-Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. *Oncotarget* 2017;8:55657–55683.
17. Hornung M, Werner JM, Schlitt HJ. Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer. *Expert Rev Anticancer Ther* 2017;17:841–850.
18. Li Y, Zhou Y-F, Liang H, et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. *World J Gastroenterol* 2016;22:6906.
19. Turaga K, Levine E, Barone R, et al. Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. *Ann Surg Oncol* 2014;21:1501–1505.

20. Sugarbaker PH, Van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. *J Gastrointest Oncol* 2016;7:29–44.
21. Raspe C, Piso P, Wiesenack C, et al. Anesthetic management in patients undergoing hyperthermic chemotherapy. *Curr Opin Anaesthesiol* 2012;25:348–355.
22. Schmidt C, Creutzenberg M, Piso P, et al. Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. *Anaesthesia* 2008;63:389–395.
23. Bell JC, Rylah BG, Chambers RW, et al. Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: a multi-institutional experience. *Ann Surg Oncol* 2012;19:4244–4251.
24. Shime N, Lee M, Hatanaka T. Cardiovascular changes during continuous hyperthermic peritoneal perfusion. *Anesth Analg* 1994;78:938–942.
25. Kanakoudis F, Petrou A, Michaloudis D, et al. Anaesthesia for intra-peritoneal perfusion of hyperthermic chemotherapy: haemodynamic changes, oxygen consumption and delivery. *Anaesthesia* 1996;51:1033–1036.
26. Li S, Zhang Y, Sun J, et al. Safe temperature range for intraoperative and early postoperative continuous hyperthermic intraperitoneal perfusion in a swine model of experimental distal gastrectomy with Billroth II reconstruction. *J Transl Med* 2013;11:181.
27. Esquivel J, Angulo F, Bland RK, et al. Hemodynamic and cardiac function parameters during heated intraoperative intraperitoneal chemotherapy using the open “coliseum technique”. *Ann Surg Oncol* 2000;7:296–300.
28. McDougall EM, Monk TG, Wolf JSJ, et al. The effect of prolonged pneumoperitoneum on renal function in an animal model. *J Am Coll Surg* 1996;182:317–328.
29. Demyttenaere S, Feldman LS, Fried GM. Effect of pneumoperitoneum on renal perfusion and function: a systematic review. *Surg Endosc* 2007;21:152–160.
30. Wauters J, Claus P, Brosens N, et al. Pathophysiology of renal hemodynamics and renal cortical microcirculation in a porcine model of elevated intra-abdominal pressure. *J Trauma* 2009;66:713–719.
31. Kashtan J, Green JF, Parsons EQ, et al. Hemodynamic effect of increased abdominal pressure. *J Surg Res* 1981;30:249–255.
32. Gerges FJ, Kanazi GE, Jabbour-Khoury SI. Anesthesia for laparoscopy: a review. *J Clin Anesth* 2006;18:67–78.
33. Oseledchik A, Zivanovic O. Intraoperative hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer. *Oncology (Williston Park)* 2015;29:695–701.
34. Talmor D, Kelly B. How to better identify patients at high risk of postoperative complications? *Curr Opin Crit Care* 2017;23:417–423.
35. Rothfield KP, Crowley K. Anesthesia considerations during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Surg Oncol Clin N Am* 2012;21:533–541.
36. Webb CAJ, Weyker PD, Moitra VK, et al. An overview of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for the anesthesiologist. *Anesth Analg* 2013;116:924–931.
37. Schmidt C, Moritz S, Rath S, et al. Perioperative management of patients with cytoreductive surgery for peritoneal carcinomatosis. *J Surg Oncol* 2009;100:297–301.
38. Holly TA, Kane GC, Joseph E, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary. *J Nucl Cardiol* 2015;22:162–215.
39. Sahai SK, Zalpour A, Rozner MA. Preoperative evaluation of the oncology patient. *Anesthesiol Clin* 2009;27:805–822.
40. Owusu-Agyemang P, Arunkumar R, Green H, et al. Anesthetic management and renal function in pediatric patients undergoing cytoreductive surgery with continuous hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin. *Ann Surg Oncol* 2012;19:2652–2656.
41. Josephs SA, Thakar CV. Perioperative risk assessment, prevention, and treatment of acute kidney injury. *Int Anesthesiol Clin* 2009;47:89–105.
42. Committee on Standards and Practice Parameters (CSPP). Standards for Basic Anesthetic Monitoring [Internet]; 2015 (p. 1–4). [Cited 10 Nov 17]. Available at: <http://www.asahq.org/quality-and-practice-management/standards-guidelines-and-related-resources/standards-for-basic-anesthetic-monitoring>.
43. Caferio T, Di Iorio C, Di Minno RM, et al. Non-invasive cardiac monitoring by aortic blood flow determination in patients undergoing hyperthermic intraperitoneal intraoperative chemotherapy. *Minerva Anesthesiol* 2006;72:207–215.
44. Thanigaimani K, Mohamed F, Cecil T, et al. The use of cardiac output monitoring to guide the administration of intravenous fluid during hyperthermic intraperitoneal chemotherapy. *Color Dis* 2013;15:1537–1542.
45. Reynolds L, Beckmann J, Kurz A. Perioperative complications of hypothermia. *Best Pract Res Clin Anaesthesiol* 2008;22:645–657.
46. Sessler DI. Perioperative thermoregulation and heat balance. *Lancet* 2016;387:2655–2664.
47. Eng OS, Dumitra S, O’Leary M, et al. Association of fluid administration with morbidity in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. *JAMA Surg* 2017;152:1156–1160.
48. Ho KM, Power BM. Benefits and risks of furosemide in acute kidney injury. *Anaesthesia* 2010;65:283–293.
49. Chenitz KB, Lane-Fall MB, Chertow GM, et al. Decreased urine output and acute kidney injury in the postanesthesia care unit. *Anesthesiol Clin* 2012;30:513–526.
50. Guo C, Wei Q, Su Y, et al. SUMOylation occurs in acute kidney injury and plays a cytoprotective role. *Biochim Biophys Acta* 2015;1852:482–489.
51. Bulacio RP, Anzai N, Ouchi M, et al. Organic anion transporter 5 (Oat5) urinary excretion is a specific biomarker of kidney injury: evaluation of urinary excretion of exosomal Oat5 after N-acetylcysteine prevention of cisplatin induced nephrotoxicity. *Chem Res Toxicol* 2015;28:1595–1602.
52. Sooriyaarachchi M, Narendran A, Gailer J. N-acetyl-L-cysteine modulates the metabolism of cis-platin in human plasma in vitro. *Metallomics* 2013;5:197–207.
53. Shalby AB, Assaf N, Ahmed HH. Possible mechanisms for N-acetyl cysteine and taurine in ameliorating acute renal failure induced by cisplatin in rats. *Toxicol Mech Methods* 2011;21:538–546.
54. Groeneveld ABJ, Navickis RJ, Wilkes MM. Update on the comparative safety of colloids. *Ann Surg* 2011;253:470–483.
55. Sheshadri DB, Chakravarthy MR. Anaesthetic considerations in the perioperative management of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Indian J Surg Oncol* 2016;7:236–243.
56. Sudaarshan G, Crawford D. Anaesthesia for intraperitoneal hyperthermic perfusion. *Anaesthesia* 1992;47:483–485.
57. De Somer F, Ceelen W, Delanghe J, et al. Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. *Perit Dial Int* 2008;28:61–66.
58. Thix CA, Königsrainer I, Kind R, et al. Ventricular tachycardia during hyperthermic intraperitoneal chemotherapy. *Anaesthesia* 2009;64:1134–1136.
59. de la Chapelle A, Perus O, Soubielle J, et al. High potential for epidural analgesia neuraxial block-associated hypotension in conjunction with heated intraoperative intraperitoneal chemotherapy. *Reg Anesth Pain Med* 2005;30:313–314.
60. Piccioni F, Casiraghi C, Fumagalli L, et al. Epidural analgesia for cytoreductive surgery with peritonectomy and heated intraperitoneal chemotherapy. *Int J Surg* 2015;16 (Part A):99–106.
61. McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. *Ann Surg Oncol* 2003;10:155–162.
62. Blumenthal S, Min K, Nadig M, et al. Double epidural catheter with ropivacaine versus intravenous morphine: a comparison for postoperative analgesia after scoliosis correction surgery. *Anesthesiology* 2005;102:175–180.
63. Desgranges F-P, Steghens A, Rosay H, et al. [Epidural analgesia for surgical treatment of peritoneal carcinomatosis: a risky technique?]. *Ann Fr Anesth Reanim* 2012;31:53–59.
64. Schmidt C, Steinke T, Moritz S, et al. Thoracic epidural anesthesia in patients with cytoreductive surgery and HIPEC. *J Surg Oncol* 2010;102:545–546.